InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,782.52
(
-2.60%
)
Post# of 252501
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 199714

Saturday, 12/24/2016 6:04:31 PM

Saturday, December 24, 2016 6:04:31 PM

Post# of 252501
2016 was bad year for biotech IPOs. Almost all biotech companies who IPOd during 2Q16 or later are currently trading below their IPO price, and those who IPOd during 1Q16 raised less money than they wanted, by and large.

A telling stat: The average proportion of insider money participating in 2016 biotech IPOs was 40%—double the average proportion during 2014-2015.

http://www.fiercebiotech.com/biotech/biotech-ipo-market-slowdown-will-it-continue-into-2017

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up